Trametinib is a mitogen-activated protein kinase (MAP2K or MEK) inhibitor that was shown to be effective as a single agent in V600 BRAF-mutated cells in NSCLC [27]. The gene discussed is WNK2; the disease is non-small cell lung carcinoma.